Skip to main content

What the FDA labels say about taking them together

Fostemsavir and mitotane

Fostemsavir's FDA label of February 13, 2024 names mitotane in its contraindications section; the mitotane label PlainMeds reads does not name fostemsavir. The fostemsavir label: “Coadministration is contraindicated due to potential for loss of therapeutic effect to RUKOBIA.”

Check it at the source: the fostemsavir FDA label on DailyMed (effective February 13, 2024, ViiV Healthcare Company); the mitotane FDA label on DailyMed (effective March 3, 2026, ESTEVE PHARMACEUTICALS, S.A.).

What does the fostemsavir label say about mitotane?

Fostemsavir label, contraindications

Mitotane o Herbal product: St John’s wort ( Hypericum perforatum )

Fostemsavir label, drug interactions

Concomitant Drug Class/Drug Name: Antineoplastic: Mitotane; Effect on Concentration of Temsavir and/or Concomitant Drug: ↓Temsavir; Clinical Comment: Coadministration is contraindicated due to potential for loss of therapeutic effect to RUKOBIA [see Contraindications ()].

Source: FDA drug label (Rukobia), ViiV Healthcare Company, effective February 13, 2024 (SPL set a21006b7-6d6f-4f06-81b4-17978756452b), via openFDA; the full label on DailyMed

What does the mitotane label say about fostemsavir?

Mitotane's label (effective March 3, 2026) does not name fostemsavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Lysodren), ESTEVE PHARMACEUTICALS, S.A., effective March 3, 2026 (SPL set 4046a224-8832-daa2-e063-6294a90a11d7), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Fostemsavir generic labelers
0Mitotane generic labelers
FostemsavirMitotane
Labeled forHIVn/a
Boxed warningNoYes
Pharmacy cost (NADAC)$156.84 per tablet 600 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?